Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 498: (TSX: $CWEB.TO) (TSXV: $PCLO.V) (TSXV: $BEER.C) (CSE: $LXX.C)
Delta, Kelowna, BC, November 19, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we will be looking at a few private and public company announcements.
Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX:CWBHF), the market leader in hemp CBD extract products, announced a collaboration between its CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program that provides a better understanding of the therapeutic uses and safety of cannabinoids.
This new scientific initiative builds on early projects that have been envisioned with Dr. Gene D. Morse, Director of the Center for Integrated Global Biomedical Sciences (CIGBS) at the University at Buffalo and State University of New York (SUNY) Distinguished Professor. The new partnership includes collaboration on a global program to advance cannabinoid sciences implementation research and safety for both supplement and biomedical use of cannabinoids with the coordination center at Buffalo, N.Y. Its purpose is to identify optimal approaches to advance the safe use of cannabinoid-containing products and identify the gaps in current knowledge. The program will include the design and implementation of novel population-based clinical informatics analysis using large databases, pilot projects that facilitate better understanding of pre-clinical and clinical pharmacology, and drug interactions to develop safe approaches to cannabinoid therapy.
"Charlotte's Web's CW Labs has an advanced team of scientists based here on the medical campus. We are excited to work with the clear leaders in the hemp sector, both in the quality of their hemp genetics and their products," said Dr. Morse.
"We realize the value of partnering our established cannabinoid product business models with an internationally recognized leader in clinical research to address the growing field of cannabinoid health and wellness products," said Tim Orr, CW Labs' Senior Vice President of Innovation. "This collaboration will oversee multidisciplinary teams conducting cutting edge research in new areas of implementation to expand the database of evidence that can guide future therapeutics development in the field. We are pleased to have established this working relationship with UB's Center for Integrated Global Biomedical Sciences and the opportunity that this new alliance creates."
Building of this multi-disciplinary team is underway. It includes UB investigators: Dr. Laszlo Mechtler, a Neurologist and Neuro-oncologist in the department of Neurology, Medical Director of the Dent Neurologic Institute and it's Cannabis Clinic and Research Center, as well as the Chief of Neuro-Oncology at Roswell Park Comprehensive Cancer Center, Dr. Jason Sprowl, a pharmaceutical scientist in the department of Pharmaceutical Sciences at UB, investigators at the University of the West Indies, Mona Campus, Jamaica, Dr. Marvin Reid, director of the Tropical Medicine Research Institute, Professor Thejani Delgoda, who leads the Natural Products Institute, and Professor Wendel Abel of Community Health and Psychiatry. At the University of Zimbabwe, Professor Charles Maponga, Director of the Clinical Pharmacology Laboratory, is engaged with planning clinical research and related regulatory policies to promote safe cannabinoid use.
The collaboration will pursue implementation research related to the wellness aspects of cannabinoids through the established national and global capacity-building efforts that form the foundation of the UB Center for Integrated Global Biomedical Sciences. This includes programs that have been developed with the Dent Neurologic Institute, home to one of the nation's largest and most comprehensive physician-directed medical cannabis programs with more than 15,000 active patients, the University of the West Indies, Mona Campus in Jamaica, and the University of Zimbabwe Center of Excellence in Pharmaceutical Innovation in the developing Health Galaxy Park site in Harare, Zimbabwe. The goal is to build a global collaboration of partners with an interest in cannabinoid sciences that includes pre-clinical and translational pharmacology, human safety, and community-based health informatics.
"These scientists bring global expertise in areas such as cellular transport mechanisms that influence cannabinoid distribution throughout the body, clinical pharmacology mechanisms that contribute to different responses among individuals and potential interactions between botanical cannabinoids and commonly used medications and will contribute to a global understanding of cannabinoids" said Dr. Morse.
Dr. Morse, and Dr. Jeffrey C. Lombardo, Program Coordinator for Global Cannabinoid Sciences, will lead the collaboration with CW Labs. Dr. Morse, Director of the Translational Pharmacology Research Core and co-Director of the Drug Development Center at UB, has extensive experience with pharmacologic assay development, designing, implementing and analyzing clinical trials with pharmacokinetics and pharmacodynamics. The collaboration with CW Labs Inc. will create a novel partnership with the Global Cannabinoids Research program at the Center for Integrated Global Biomedical Sciences.
PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) and MINO Labs S.A. de C.V., the founders of PharmaCielo S.A. de C.V., congratulate Mexican Senate members for advancing the much-needed cannabis legislation and subsequent reform by voting to move forward the legalization bill, which includes provision for import of medicinal extracts and products.
David Attard, CEO of PharmaCielo Ltd., says, "The recent vote is an important development and positive momentum toward bringing cannabis reform to the finish line by the mid-December deadline. The partnership we established with MINO Labs last year as PharmaCielo Mexico is a precursor to what we expect will become an important and vibrant market for cannabis-derived health and wellness products, for which we aim to become a primary supplier of high-quality medicinal-grade oils and isolates."
Manuel Cosme Odabachian, CEO of MINO Labs, stated, "Mexican lawmakers made it loud and clear today that adult cannabis usage should be legalized. The Senators' votes in favor of the new bill are a huge step forward and a development welcomed by both end-users and industry participants. For the past 20 years, MINO Labs has been a leading specialty supplier and distributor of pharma-grade products in Mexico. Together with PharmaCielo we have built a great infrastructure to provide the Mexican market with top-notch cannabis extract product offerings – and we are ready to deliver!"
PharmaCielo and MINO Labs founded PharmaCielo Mexico last year as a joint venture. The purpose of the joint venture is to bring PharmaCielo's high-quality cannabis extracts and derivative products from its Colombian cultivation and processing centre to the Mexican market by leveraging MINO Labs' extensive experience and broad presence in the country's pharma distribution space. Upon completion of the legislative process, PharmaCielo Mexico will commence the sale and distribution of medicinal cannabis products, including those for wellness and lifestyle segments, in Mexico.
Distribution of cannabis products by PharmaCielo in Mexico will be subject to the approval of the TSX Venture Exchange (the "TSXV").
Hill Street Beverage Company Inc. (TSXV: BEER) announced that it has signed a definitive agreement to acquire the primary assets of Lexaria Canpharm, the cannabis-related division of Lexaria Bioscience Inc. (CSE: LXX). This acquisition provides Hill Street with the exclusive rights in perpetuity to use Lexaria's ground-breaking DehydraTECHTM patent portfolio on a global basis to make any type of products containing THC and other psychoactive cannabinoids. In addition, the agreement expands Hill Street's license with Lexaria HempCo to make products containing CBD on a global basis for ten years.
Terms of the acquisition
● Total consideration of $3.85 million, including $350K in cash upon closing and future payments of $2.0 million.
● Hill Street will issue Lexaria Bioscience a total of $1.5MM worth of Common Shares in the capital of the Company in three equal installments with the first tranche issuable on closing. The first tranche will be issued at a price of $0.0829 per share, which is equal to the 10-day volume weighted average closing price of the Common Shares on the TSX Venture Exchange on the date hereof. All successive issuances shall be issued at the greater of (A) the 10-day volume weighted average closing price of the Common Shares on the TSX Venture Exchange on such payment date; and (B) $0.0829;
With over sixty patents for DehydraTECHTM either issued or pending, this transaction positions Hill Street to expand its strategy of producing ingredients for Cannabis 2.0 products, allowing the Company to take advantage of growing demand for "quick onset and duration" recreational cannabis edibles and topicals. This transaction will allow Hill Street to expand its addressable market to every country in the world where cannabis is either medicinally or recreationally legal. Lexaria's Intellectual Property converts perishable cannabis products such as oils and extracts into shelf stable powders. Hill Street will manufacture these powders for sale to licensed cannabis processors at its own facility as well as sub-license the technology to licensed manufacturers globally. Shelf stable cannabis powders are the ideal ingredients upon which to build world class Cannabis 2.0 brands, including beverages, edibles, and topicals. The DehydraTECHTM processes are well researched, market validated, and well protected through multiple patents, and will continue to improve as Lexaria continues its research.
Completion of the transaction is subject to the approval of the TSX Venture Exchange.
"With this transaction, we are building on an already strong partnership with Lexaria. We are gaining full ownership of the joint manufacturing partnership we created last year, and positioning Hill Street to become an early leader in the global market for cannabis 2.0 ingredients and products. Our cannabis processing facility is designed specifically to produce shelf stable ingredients using DehydraTECHTM for the Cannabis 2.0 market," said Terry Donnelly, Chairman & CEO of Hill Street. "With a significant portion of the consideration in shares and future payments, this transaction demonstrates Lexaria's faith in Hill Street to unlock the value of their innovations for their shareholders based on our success."
"Hill Street's team is executing a new and exciting strategy in the cannabis sector, designed to take advantage of the Cannabis 2.0 market and enhanced consumer expectations," stated Chris Bunka, Chairman & CEO of Lexaria Bioscience. "Their deep expertise in consumer goods will allow consumers to experience Lexaria's innovations through the highest performance products available in the Cannabis 2.0 sector. Lexaria's focus remains on creating the greatest innovations possible in drug delivery in the diverse sectors of nicotine, cannabinoids, and antivirals for both the therapeutic and pharmaceutical industries. Innovations in drug delivery in the pharmaceutical industry represents a massive global opportunity for Lexaria, and this transaction with Hill Street assists our ability to focus, while providing our shareholders with a significant carried interest in a fast growing startup well positioned for success in the cannabis 2.0 market."
Canndora, the global media and event platform, and initiative created by Marigold Marketing & PR to support advancing women in emerging industries has announced it is hosting #CanndoraConnect: Women in Psychedelics event.
A virtual event, #CanndoraConnect: Women in Psychedelics is open to audiences worldwide and will take place 2:00-4:00 p.m. EST on Wednesday, December 2nd, 2020. The event will offer attendees a unique experience, providing collaboration, networking, inspiration, and advice for women's success in the emerging psychedelics industry worldwide.
“We are honoured to be partnering with Canndora to create a movement that is bringing awareness and attention to advancing women in the emerging psychedelics industry,” says Todd Shapiro, CEO & Director of Red Light Holland. “This is an exciting event that will provide amazing opportunities to network, learn, connect and feel inspired by all of the extraordinarily intelligent speakers and panellists, including Ann Barnes and Sarah Hashkes, whom we are proud and grateful to work so closely with at Red Light Holland.”
Attendees will hear from influential speakers, learn best industry practices for success, and network with leading industry experts in psychedelics. The event will feature notable industry professionals and panelists who will share their expertise on critical topics, including opportunities for international business in psychedelics and the science behind psilocybin and its role in women's health.
Industry leaders and speakers in attendance include:
● Ann Barnes, Director of Red Light Holland
● Sarah Hashkes, CEO of Radix Motion
● Terri Smith, Chief Mycologist of WAKE
● Dr. Olga Chernoloz, Chief Scientific Officer of WAKE
● Susan Chapelle, President of Havn Life
● Irie Selkirk, Co-founder & Director of Rise Wellness Retreats
“2020 is the year the voice of psychedelic renaissance has been heard the loudest,” says Dr. Olga Chernoloz, Chief Scientific Officer of WAKE. “So far the data streaming from the psychedelic clinical studies has been exceptionally promising. It gives hope to the development and recognition of new treatment modalities for the support of mental health. Women, often disproportionately affected by these conditions, could find a way to re-process the underlying emotional content and find balance with help of the psychedelic-assisted therapy.”
Now hosting its seventh professional event for emerging industries, including sell-out attendance in previous cannabis women-focused events, the #CanndoraConnect: Women and Psychedelics event is positioned to be a hailed success. The event is made possible with support from presenting partners, Red Light Holland (CSE: TRIP) (OTC: TRUFF) and WAKE.
The #CanndoraConnect: Women in Psychedelics event is open to anyone 19+. Tickets are CAD$15.00 and attendees are encouraged to register as soon as possible as spaces are limited. To purchase tickets, register on Eventbrite.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
800 665 0411